Health Trials

About this trial

The goal of this observational study is to collect data on efficacy and safety of microwave ablation (MWA) used to treat subjects with primary and secondary liver malignancies and renal malignancies. The main question it aims to evaluate the short, medium and long-term clinical course of patients treated with MWA.

Participants will not alter their normal clinical and therapeutic practice, due to the observational nature of the study, and all data regarding microwave treatments will be collected (including demographic data). follow their normal clinical and therapeutic path

Eligibility criteria

Qualifiers

> 18 years with primary or secondary liver tumors or small kidney tumors that are not candidates for surgery or cannot be radically resected by surgery alone

Primary liver cancer: up to three liver nodules ≤ 3 cm

Secondary hepatic tumours: up to nodules ≤ 3 cm provided that the objective is complete hepatic clearance Renal tumours: single or multiple (von Hippel Lindau syndrome), < 4 cm

Disqualifiers

pregnant women

non-manageable coagulopathies

Extended extrahepatic or extrarenal disease

for liver ablation: presence of bilio-digestive anastomosis

Trial design

Treatments tested in this trial

  • Microwave ablation (MWA)

Treatment groups

500 Participants
are divided into 2 treatment groups

Locations

1
IRCCS Ospedale San Raffaele20153, Milan Italy

Sponsors and collaborators

Francesco De Cobelli

Lead sponsor

IRCCS San Raffaele

Sponsor institution

Source ClinicalTrials.gov